About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01423734

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatm...

Lead sponsor: Memorial Sloan Kettering Cancer Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Memorial Sloan Kettering Cancer Center

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histopathologic evidence of well differentiated neuroendocrine tumor of gastroenteropancreatic origin
•Evidence of metastatic disease of at least 2.0 cm in the liver by MRI or CT imaging.
•Patient ≥18 years of age on the day of signing informed consent.

Exclusion Criteria

•Any contraindication to MRI based on departmental MR questionnaire
•Inability to cooperate for an MR exam
•Patient has a history of a second active malignancy with evidence of metastases. Patients with a history of resected prior malignancy or one that would not interfere with the MRI results is allowed.
•Patient has known psychiatric or substance abuse disorders that would, in the opinion of the treating investigator, interfere with cooperation with the requirements of the trial.

Related studies

Active Not RecruitingPhase 3

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488 · Gastro-enteropancreatic Neuroendocrine Tumor

Active Not RecruitingPhase 2

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

NCT03600233 · Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, and more

Active Not RecruitingPhase 3

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942 · Gastro-enteropancreatic Neuroendocrine Tumor

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

NCT03889093 · Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

NCT06253897 · Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 23, 2023Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment20

Start dateAug 2011

Last updatedJan 23, 2023

Condition

Gastro-enteropancreatic Neuroendocrine Tumor Secondary Malignant Neoplasm of Liver

Locations shown

Memorial Sloan Kettering Cancer Center

New York, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2023Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions